Transforming Cancer Screening and Diagnosis
Saving and Improving Lives
Innovative liquid biopsy for early detection and diagnosis of cancer
when it matters most
(Cancer Associated Macrophage-Like Cells)
Early Detection of Cancer and Recurrence
Cancer Screening
Residual Disease
Detection of Recurrence
CAMLs
25-300 µm in Size
Present in Cancers of All Stages
Detected in More Than 30 Types of Cancer
Determination of Cancer Aggressiveness
Companion/Complementary Diagnostics
Cancer Diagnostics
Monitoring Therapy
Assay Applicable to All Cancers
Enhance Patient Selection
Provide Prognosis at Any Time
Provide Information on Treatment Response
Provide Companion Diagnostics - Not Requiring Tissue
Validate Drug Targets
Deliver High Quality DNA for Sequencing
Streamline Drug Development and Clinical Trials
CTCs
(Circulating Tumor Cells)
8-25 µm in Size
Present in Late Stage Cancers
Detected in Breast, Prostate, Colorectal, and Small Cell Lung Cancers
Early Determination of Response to Therapy
Sequential Monitoring of Tumor Marker Status During Therapy
Monitoring change of PD-L1 Expression
